WallStSmart

DaVita HealthCare Partners Inc (DVA)vsGuardian Pharmacy Services, Inc. (GRDN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 850% more annual revenue ($13.84B vs $1.46B). DVA leads profitability with a 5.7% profit margin vs 3.6%. DVA trades at a lower P/E of 20.1x. DVA earns a higher WallStSmart Score of 70/100 (B-).

DVA

Strong Buy

70

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22

GRDN

Hold

50

out of 100

Grade: D+

Growth: 7.3Profit: 6.5Value: 4.0Quality: 7.0
Piotroski: 3/9Altman Z: 5.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVASignificantly Overvalued (-17.0%)

Margin of Safety

-17.0%

Fair Value

$123.34

Current Price

$192.16

$68.82 premium

UndervaluedFair: $123.34Overvalued

Intrinsic value data unavailable for GRDN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA4 strengths · Avg: 9.0/10
Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Debt/EquityHealth
-17.5010/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.658/10

Growing faster than its price suggests

EPS GrowthGrowth
43.5%8/10

Earnings expanding 43.5% YoY

GRDN4 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
5.3010/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
24.0%9/10

Every $100 of equity generates 24 in profit

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
39.0%8/10

Earnings expanding 39.0% YoY

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

GRDN4 concerns · Avg: 3.5/10
Price/BookValuation
11.6x4/10

Trading at 11.6x book value

Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, Debt/Equity, PEG Ratio. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bull Case : GRDN

The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Debt/Equity.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : GRDN

The primary concerns for GRDN are Price/Book, Revenue Growth, Profit Margin. A P/E of 51.3x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

DVA is growing revenue faster at 6.0% — sustainability is the question.

DVA generates stronger free cash flow (219M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (70/100 vs 50/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Guardian Pharmacy Services, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions focused on the long-term care sector, serving assisted living and skilled nursing facilities. The company is recognized for its commitment to personalized medication management, high standards of quality and compliance, and superior customer service. By utilizing advanced technology and deep pharmaceutical expertise, Guardian not only improves patient outcomes but also streamlines operations for healthcare partners. With a substantial operational presence in multiple states, Guardian is well-equipped to address the growing demand for tailored pharmacy services in a rapidly evolving healthcare environment.

Want to dig deeper into these stocks?